EGFR, AKT1, HSP90AA1, ESR1, MMP9 potential pathways of interaction with most genes, including the MAPK, P13K–Akt, FoxO, mTOR, and Phospholipase D signaling pathways, suggesting that these genes may have a role in the treatment of NAFLD and DM comorbidity. This evidence concerns the gene MMP9 and metabolic dysfunction-associated steatotic liver disease.